Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01241721 · ClinicalTrials.gov registry record · NA

Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer

A NA study of Breast Cancer and Breast Cancer Surgery, sponsored by Swedish Medical Center.

Completed
Registry status
NA
Development phase
34
Enrollment target
2
Study locations

NCT01241721: Completed NA study of Breast Cancer and Breast Cancer Surgery, sponsored by Swedish Medical Center.

NCT01241721 is a NA study of Breast Cancer and Breast Cancer Surgery that has completed, run by Swedish Medical Center. The registered enrollment target is 34 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01241721, a NA study of Breast Cancer and Breast Cancer Surgery, has completed, sponsored by Swedish Medical Center.

COMPLETED
Registry status
NA
Development phase
34 participants
Enrollment target
2
Study locations

Study Summary

The purpose of the study is to determine the optimal, lowest dose of radioactive tracer required for Positron Emission Mammography (PEM), and the accuracy and reliability of PEM in pre-surgical evaluations for patients with newly diagnosed breast cancer anticipating breast-conserving surgery but identified to have a second unsuspected breast cancer by MRI.

Interventions

  • DEVICE Positron Emission Mammography (PEM)

Study Locations (2)

Washington

  • Swedish Cancer Institute - Seattle
  • Swedish Cancer Institute Cherry Hill Campus - Comprehensive Breast Center - Seattle

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2010-09
Est. Completion 2016-04
Phase NA
Swedish Medical Center

30 total trials

What the finished NCT01241721 record still lists

NCT01241721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Positron Emission Mammography (PEM) is the first listed.

NCT01241721 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT01241721 about?

NCT01241721 is a clinical study titled "Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer". The purpose of the study is to determine the optimal, lowest dose of radioactive tracer required for Positron Emission Mammography (PEM), and the accuracy and reliability of PEM in pre-surgical evaluations for patients with newly diagnosed breast cancer anticipating breast-conserving surgery but ide...

What is the current status of trial NCT01241721?

This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2010-09. Estimated completion is 2016-04.

What conditions does trial NCT01241721 study?

This clinical trial studies the following conditions: Breast Cancer, Breast Cancer Surgery.

What interventions are being tested in trial NCT01241721?

The interventions under investigation include: Positron Emission Mammography (PEM) (DEVICE).

Who is sponsoring clinical trial NCT01241721?

This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01241721 being conducted?

This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01241721's enrollment target sits among peer trials

34 928th of 1224 higher than 291 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01241721, the US trial registry maintained by the National Library of Medicine. NCT01241721 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.